Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,838 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metastatic Skin Cancer Clear all

Conditions: Uveal Melanoma
Interventions: AEB071, BYL719; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Miami, Florida • New York, New York

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy, Magnetic Resonance Imaging, Nivolumab, Prednisone, Sirolimus; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 26
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more

Conditions: Triple Negative Breast Neoplasms
Interventions: ladiratuzumab vedotin, Pembrolizumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more

Conditions: Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions: Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tumor, Metastatic Melanoma, Melanoma
Interventions: OBX-115, Acetazolamide, Cyclophosphamide, Furosemide, Mesna, Fludarabine Phosphate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: Sacituzumab govitecan, Naxitamab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Photon, Proton; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 21 Years and older
Enrollment: 1,238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2036
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 33 more

Conditions: Melanoma (Skin)
Interventions: bevacizumab, carboplatin, everolimus, paclitaxel; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 310
States / cities: Scottsdale, Arizona • Martinez, California • Mountain View, California + 214 more

Conditions: Recurrent Melanoma, Stage IV Skin Melanoma
Interventions: NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12, MART-1 Antigen, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma (Skin)
Interventions: filgrastim, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation; Biological · Drug · Procedure
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 16 Years to 44 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Metastatic Melanoma
Interventions: MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumors
Interventions: ASP1951, pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more

Conditions: Metastatic Breast Cancer
Interventions: lapatinib; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 3
States / cities: Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri

Conditions: Metastatic Melanoma, Absence of CNS Metastases
Interventions: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells; Biological
Lead sponsor: Scott Pruitt; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: vinorelbine tartrate; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 65 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 18
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more

Conditions: Melanoma
Interventions: Dabrafenib, Trametinib, Trametinib placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Metastatic Melanoma, Nausea
Interventions: Not listed
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Panobinostat, Trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Norwalk, Connecticut + 4 more

Conditions: Recurrent Melanoma, Stage IV Melanoma
Interventions: recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumor
Interventions: DB-1310, Trastuzumab, Osimertinib, capecitabine; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more

Conditions: Breast Cancer
Interventions: PET (positron emission tomography); Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Melanoma, Carcinoma, Renal Cell
Interventions: rh IL-15; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Unresectable Malignant Neoplasm
Interventions: Laboratory Biomarker Analysis, Muscadine Grape Skin Extract, Quality-of-Life Assessment; Diagnostic Test · Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

Vinorelbine in Treating Older Women With Stage IV Breast Cancer

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Vaccine Therapy in Treating Patients With Metastatic Melanoma

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery

A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery